Fintel reports that on October 31, 2025, Cantor Fitzgerald maintained coverage of Eli Lilly and (NYSE:LLY) with a Overweight ...

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

NEW YORK (AP) — The U.S. stock market is drifting around its record heights on Thursday, as Wall Street sifts through mixed developments on everything from the U.S.-China trade war to profits for Big ...

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...

Lilly appears to have triumphed over Novo Nordisk in the battle for the weight-loss market. While both stocks are down from ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...